 ATLANTA, Oct. 4, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase or Company, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced interim three-month results from its ongoing chronic toxicology studies of oral IkT-148009 administered in rats and non-human primates NHPs. The Companys ongoing toxicology studies of IkT-148009 are designed to meet the regulatory requirements for chronic dosing in humans, which include daily oral administration in rats for six months and in NHPs for nine months. 